/

SXTP

60 Degrees Pharmaceuticals, IncClosed

0.9000+0.01 +0.81%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 0.9180 +2.00%

Open

0.9110

Prev close

0.8928

Day range

0.88000.9420

52-week range

0.84008.62

Volume

36.59K0.28×

Mkt cap

3.17M

P/E ttm

—

Fwd P/E

-0.25

EPS ttm

-5.34

Div yield

0.00%

Earnings

—

From 52w high

−89.56%

Price Chart

Yahoo Finance · delayed

SXTPOct 13, 2026O 0.8870H 0.9420L 0.8750C 0.9000−0.0160 (−1.75%)Vol 37.50K

SMA 501.0825
SMA 2001.8544

1Y change −86.02% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

SXTP 60 Degrees Pharmaceuticals, Inc · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −18.92%
1 month: 0.00%
3 months: −38.36%
6 months: −59.46%
Year to date: −55.71%
1 year: −86.02%

Valuation & ownership

Market cap: 3.17M
Enterprise value: 11.78M
P/E (ttm): —
Forward P/E: -0.25
PEG ratio: —
Price / book: —
Price / sales (ttm): 2.61
EV / EBITDA: -1.39
EPS (ttm): -5.34
EPS (forward): -3.58
Beta (5y monthly): 2.40
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 3.52M
Float: 2.45M
Short % of float: 3.82%
Short ratio (days): 1.73
Held by insiders: 19.39%
Held by institutions: 17.11%
Avg volume (3m): 132.18K
50-day average: 1.09
200-day average: 1.86
52-week change: −86.02%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 38.2
vs 50-day SMA: −16.86%
vs 200-day SMA: −51.47%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 15.71%
Realised vol (20d, ann.): 136.7%
From 52-week high: −89.56%
From 52-week low: +7.14%

ANR

Analyst Consensus

1 analysts

Consensus

—

Mean target

3.70

+311.11% implied

Low 3.70Median 3.70High 3.70

Recommendation trend

Now1 / 1 / 0

Buy / hold / sell counts

Financial Snapshot

Full statements →

DES

About 60 Degrees Pharmaceuticals, Inc

Yahoo Finance profile

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue fever. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Washington, District Of Columbia.

Sector: Healthcare
Industry: Biotechnology
Employees: 3
Headquarters: Washington, DC, United States
Website: 60degreespharma.com
Officers: Dr. Geoffrey Stuart Dow Ph.D. Chairman, CEO & President
Mr. Tyrone Miller Chief Financial Officer
Ms. Kristen Landon Chief Commercial Officer
Dr. Bryan Smith Chief Medical Officer

SEAS

Seasonality · SXTP

2023–2026 · monthly returns

Strongest month Apr +16.89%Weakest month Jan −58.13%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	104.2	-25.1	-43.7	-9.7	-5.7	18.1	-33.5	-7.7	23.1	-32.3			−55.7%
2025	-43.7	-50.1	1.7	45.7	-3.7	-8.1	-43.5	5.2	5.0	-8.1	-22.1	-52.1	−92.1%
2024	-72.5	-3.6	-3.3	-11.9	27.0	-13.4	-41.5	-24.5	-6.7	-38.3	37.5	21.7	−89.5%
2023								-37.5	-47.1	-22.6	8.2	64.5	−54.5%

INSD

Insider Activity · SXTP

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jun 11, 2026	Dow Geoffrey SChief Executive Officer	Purchase at price 1.38 per share.	7.3K	$10.13K
Dec 14, 2025	Dow Geoffrey SChief Executive Officer	Purchase at price 0.80 per share.	9.7K	$7.76K
Dec 10, 2025	Dow Geoffrey SChief Executive Officer	Purchase at price 0.92 - 0.95 per share.	13K	$12.20K
Sep 11, 2025	Dow Geoffrey SChief Executive Officer	Stock Award(Grant) at price 1.39 per share.	7.2K	$10.00K
Jun 8, 2025	Dow Geoffrey SChief Executive Officer	Stock Award(Grant) at price 2.99 per share.	4.4K	$13.06K
Jun 2, 2025	Xu CherylDirector	Purchase at price 2.87 - 2.90 per share.	5K	$14.41K
Jan 16, 2025	Dow Geoffrey SChief Executive Officer	—	14.4K	—
Jan 16, 2025	Miller TyroneChief Financial Officer	—	11.6K	—
Jan 16, 2025	Landon KristenChief Operating Officer	—	4.5K	—
Dec 15, 2024	Xu CherylDirector	Purchase at price 1.45 - 1.85 per share.	13K	$21.40K
Dec 8, 2024	Dow Geoffrey SChief Executive Officer	Purchase at price 1.11 - 1.27 per share.	74K	$89.75K
Nov 20, 2024	Dow Geoffrey SChief Executive Officer	Purchase at price 0.90 - 0.92 per share.	7K	$6.37K

SXTP

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

SXTP

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About 60 Degrees Pharmaceuticals, Inc

Seasonality · SXTP

Insider Activity · SXTP

Congress Trades · SXTP

Investors Holding SXTP

Investors Holding SXTP

Congress Trades · SXTP

Insider Activity · SXTP

Seasonality · SXTP

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About 60 Degrees Pharmaceuticals, Inc

Earnings & Dividends

News